Clinical Conversations (CE): GLP Practice Insights: GLP-1 Receptor Agonists and Neurodegenerative Disorders (CE)

This session discusses the potential sites of action and benefits for GLP-1 agonists (GLP-1a) in the pathology of two neurodegenerative disorders, Alzheimer’s Disease (AD) and Parkinson’s Disease (PD). This session will also review the published and pending clinical literature of FDA approved GLP-1a use in AD and PD. The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.